Bifogade filer
Kurs & Likviditet
Prenumeration
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
July – September 2022
• Net sales: 5,213 (0) TSEK.
• Other operating revenues: 8,313 (423) TSEK.
• Profit from financial items: 3,953 (-10,225) TSEK.
• Earnings per share: 0.20 (-0.52) SEK.
January – September 2022
• Net sales: 21,354 (0) TSEK.
• Other operating revenues: 21,280 (6,380) TSEK.
• Profit from financial items: 5,785 (-36,483) TSEK.
• Earnings per share: 0.29 (-2.22) SEK.
• Cash and cash equivalents as per the end of the reporting period: 144,940 (66,087) TSEK.
• Equity ratio as per the end of the reporting period: 96 (95)%.
Events during the period
• CombiGene strengthens its management capacity through the recruitment of Peter Ekolind as COO.
Events after the end of the period
• There have been no significant events after the end of the period.